Hologic Inc. saw its revenues increase 2 percent to $625 million in its second fiscal quarter, powered largely by its 3-D mammography technology.

Breast-health revenues grew 8.5 percent to $238.7 million, while skeletal-health revenues rose 4.7 percent to $23.5 million. The company attributed the increases to growing sales of bone densitometry and 3-D mammography systems. Increased sales from the Aptima product line were also seen, with growth in blood-screening revenues.

Meanwhile, diagnostics revenues fell 1.9 percent to $290.8 million, and gynecological surgical revenues dropped 2.2 percent to $72.0 million. The company attributed the decline to the $10.6 million sale of its Lifecodes subsidiary to Immucor last year. Decreases in Pap test sales and the decline of 2-D systems compounded that decrease.